Cardiac arrest patients may be more likely to survive and avoid permanent disabilities when bystanders use a defibrillator to treat them before an ambulance arrives, a new study suggests.
Wilson’s disease patients had been champing at the bit for Teva’s generic version of Syprine that the company called a “lower-cost generic.” But after the drug launched in February 2018, patients discovered that Teva’s generic is not eally that much cheaper than Valeant Pharmaceuticals International’s branded drug.
Shares of ObsEva climbed after the company highlighted a data point from a late-stage trial that showed its fertility treatment nolasiban was successful in improving the pregnancy rate of some women following in vitro fertilization.
Eli Lilly published results from a new Phase IIIb study of Trulicity (dulaglutide) in combination with a SGLT-2 inhibitor showing improved blood sugar control in adults with type 2 diabetes.
ARCA biopharma, based in Westminster, Colorado, announced results from its Phase IIb clinical trial of Gencaro (bucindolol hydrochloride) in patients with atrial fibrillation.
A U.S. administrative court said it has the authority to decide the validity of patents Allergan transferred to a Native American tribe.
Mobile data will be used in Ghana to track and control epidemics, helping prevent a repeat of the 2014 West Africa Ebola outbreak, in a pioneering program announced by Vodafone Foundation.
KemPharm Inc. said the U.S. Food and Drug Administration approved the drugmaker’s opioid painkiller Apadaz for the short-term management of acute pain.
Teva Pharmaceuticals Inc. made more cuts in the United States, this time to real estate holdings. To save money, the company will close its offices in Washington, D.C. and New York City. No jobs were reported to be lost from the cuts.
The passing of tax reform led most analysts to predict that 2018 will be a strong year for mergers and acquisitions. Yet, despite what appears like a good start to the year, not all companies are jumping immediately on the M&A bandwagon.